Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury?

Phase 1

• Conditions: Reperfusion after an ischemic accident will limit tissue damage (infacrt size), though on the other hand reperfusion injury will also cause tissue damage by the release of ROS and facilitating cellular apoptosis. Means to inhibit and-or decrease the reperfusion injury, can prevent further damage thereby prevent further mortality or morbidity.; MedDRA version: 8.1Level: LLTClassification code 10062828Term: Ischemic heart disease prophylaxis

• Registration Number: EUCTR2006-004878-28-NL
• Lead Sponsor: MCN farm-tox

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-06-14
• Last Update Posted: 21 December 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

-healthy male volunteers
-aged 18-50 years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-cardiovascular disease
-hypertension (systole > 140 mmHg, diastole > 90 mmHg)
-hypercholesterolemia (fasting total cholesterol > 5 mmol/l)
-diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
-asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
-participation in any clinical trial during the last 60 days prior to this study.
-administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified